Outlook Therapeutics, Inc. Share

Market capitalization is the share price multiplied by the number of shares issued.

Outlook Therapeutics, Inc.

Enterprise value (EV) is a measure of the value of a company regardless of its financing. It is calculated as follows:
EV = market capitalization - cash + debt.

Enterprise Value explained simply

Outlook Therapeutics, Inc.

The P/E ratio or price/earnings ratio TTM (Trailing Twelve Months) over the last 12 months describes the ratio of the share price to earnings per share.

Outlook Therapeutics, Inc.

If you divide the enterprise value by the free cash flow of the last 12 months, you obtain an important key figure for assessing the valuation of companies - even if they are not yet generating profits.

Outlook Therapeutics, Inc.

The P/B ratio TTM (Trailing Twelve Months) over the last 12 months describes the ratio of the share price to the book value per share.

Outlook Therapeutics, Inc.

Turnover TTM (Trailing Twelve Months) represents the sum of all revenues of a company for its products, services or other items within the last 12 months.

Outlook Therapeutics, Inc.

EBIT or the operating result represents the profit or loss after deducting direct costs (cost of sales), sales, marketing, administrative, research and development costs and depreciation and amortization.

Outlook Therapeutics, Inc.

The free cash flow TTM (Trailing Twelve Months) provides information on how much of the profit generated over the last 12 months remains in the company's coffers and is therefore available for profit distributions, share buybacks or debt repayment.

Outlook Therapeutics, Inc.

Cash is defined as cash and cash equivalents (i.e. cash items of very high value).

Outlook Therapeutics, Inc.

EPS TTM (Trailing Twelve Months) or earnings per share represents the profit per share over the last 12 months. The company's net profit is divided by the number of shares.

Outlook Therapeutics, Inc.

Price/earnings ratio based on the expected net earnings per share for the financial year ending at Sep 30 2024.

Outlook Therapeutics, Inc.